AB

Aaron Brinkworth

Resonance Health Limited | Non-Executive Director
Mr Brinkworth had a 22-year career with Gilead Sciences, Inc. during which time the company grew from a small biotech-pharma company to a multi-billion-dollar global company with annual sales of over USD $27 billion. He held several commercial, licensing, and patient access roles at Gilead, including that of Executive Director - Global Patient Solutions, where he was responsible for commercial and access strategies for emerging markets.

Companies and Roles

Company
Title
Tenure
Since
RHT
RHT
Resonance Health Limited
  • Non-Executive Director
2yrs, 2mthMar 2023
PIQ
PIQ
Proteomics International Laboratories Ltd
  • Non-Executive Director
7mthNov 2024

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
RHT
RHT
Resonance Health Limited
09/04/251,107,647N/AN/AN/A
PIQ
PIQ
Proteomics International Laboratories Ltd
08/11/240N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
RHT
RHT
Resonance Health Limited
09/04/25
Buy
259,475$0.002$520On-market trade
RHT
RHT
Resonance Health Limited
08/04/25
Buy
267,083$0.073$19,454On-market trade
RHT
RHT
Resonance Health Limited
07/04/25
Buy
272,885$0.036$9,959On-market trade
RHT
RHT
Resonance Health Limited
04/04/25
Buy
8,204$0.037$303On-market trade
RHT
RHT
Resonance Health Limited
05/09/23
Buy
300,000$0.066$19,676On-market trade